• Mutation; HGNC; HGNC:1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583).
  
• Mutation; HGNC; HGNC:7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583).
  

DOI=10.1093/jnci/59.2.301
Quinn L.A., Woods L.K., Merrick S.B., Arabasz N.M., Moore G.E.
Cytogenetic analysis of twelve human malignant melanoma cell lines.
J. Natl. Cancer Inst. 59:301-307(1977)

PubMed=72600
Sharma B.
In vitro immunization against human tumor cells with tumor cell fractions.
Cancer Res. 37:4660-4668(1977)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978)

PubMed=6277475
Frampton R.J., Suva L.J., Eisman J.A., Findlay D.M., Moore G.E., Moseley J.M., Martin T.J.
Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.
Cancer Res. 42:1116-1119(1982)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3180053
Lemontt J.F., Azzaria M., Gros P.
Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells.
Cancer Res. 48:6348-6353(1988)

PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997)

PubMed=15048078; DOI=10.1038/sj.onc.1207563
Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G., Meltzer P.S., Ringner M., Hayward N.K.
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004)

PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Stark M.S., Hayward N.K.
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007)

PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676
Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V., Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M., Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Mol. Cancer Ther. 11:888-897(2012)